{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:21:14Z","timestamp":1789154474422,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The unique properties of dalbavancin (DAL) emphasize the need to explore its clinical benefits to treat periprosthetic joint infections (PJIs). The present study aimed to compare the treatment outcome of dalbavancin with Standard of Care (SoC) in hip and knee PJIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eighty-nine patients were selected for each group of this study based on our prospectively maintained PJI database. A 1:1 propensity score-matching was performed between patients who received at least two doses of dalbavancin and those who received SoC. Patients were matched based on demographics, joint, patient risk factors, Musculoskeletal Infection Society (MSIS) criteria, surgical management and type of infection. Treatment outcome was evaluated considering re-infection and re-revision rates, safety and tolerability of dalbavancin after a minimum of 1\u2005year follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Infection eradication was achieved in 69 (77.5%) and 66 (74.2%) patients of the DAL and SoC groups, respectively. Thirteen (14.6%) patients in the DAL group and 12 (13.5%) patients in the SoC group had an infection-related re-revision. The most prevalent microorganisms among the two groups were Staphylococcus epidermidis (32.3%), Staphylococcus aureus (13.8%) and Cutibacterium spp. (11.3%). There were significantly less Gram-positive bacteria (P\u200a=\u200a0.03) detected in patients who received dalbavancin (17.4%) treatment compared with those treated with SoC (48.0%) in culture-positive re-revisions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dalbavancin treatment for Gram-positive PJIs resulted in a similar outcome to SoC, with excellent safety and low rate of adverse effects. Dalbavancin seems to be a promising antimicrobial against PJIs by reducing the risk of Gram-positive re-infections and allowing a less frequent dosage with potential outpatient IV treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac178","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T11:52:29Z","timestamp":1654775549000},"page":"2274-2277","source":"Crossref","is-referenced-by-count":32,"title":["Dalbavancin in Gram-positive periprosthetic joint infections"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-4648","authenticated-orcid":false,"given":"Sebastian","family":"Simon","sequence":"first","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"},{"name":"2nd Department, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard J H","family":"Frank","sequence":"additional","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Hinterhuber","sequence":"additional","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reitsamer","sequence":"additional","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Aichmair","sequence":"additional","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"},{"name":"2nd Department, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dominkus","sequence":"additional","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"},{"name":"School of Medicine, Sigmund Freud University Vienna , Freudplatz 1, 1020 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"S\u00f6derquist","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro , Sweden"},{"name":"Department of Laboratory Medicine, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen G","family":"Hofstaetter","sequence":"additional","affiliation":[{"name":"Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"},{"name":"2nd Department, Orthopaedic Hospital Vienna-Speising , Speisinger Stra\u00dfe 109, 1130 Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"2022072817544503100_dkac178-B1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.arth.2018.02.078","article-title":"The 2018 definition of periprosthetic hip and knee infection: An evidence-based and validated criteria","volume":"33","author":"Parvizi","year":"2018","journal-title":"J Arthroplasty"},{"key":"2022072817544503100_dkac178-B2","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.3390\/jcm10215180","article-title":"Analysis of failed two-stage procedures with resection arthroplasty as the first stage in periprosthetic hip joint infections","volume":"10","author":"Simon","year":"2021","journal-title":"J Clin Med"},{"key":"2022072817544503100_dkac178-B3","doi-asserted-by":"crossref","first-page":"114901","DOI":"10.1016\/j.diagmicrobio.2019.114901","article-title":"In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times","volume":"96","author":"Di Pilato","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022072817544503100_dkac178-B4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgar.2020.11.018","article-title":"Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections","volume":"24","author":"Wang","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2022072817544503100_dkac178-B5","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/cid\/ciy941","article-title":"Dalbavancin dosage","volume":"68","author":"Tobudic","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022072817544503100_dkac178-B6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2022072817544503100_dkac178-B7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in Gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2022072817544503100_dkac178-B8","first-page":"532","article-title":"Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study","volume":"32","author":"Buz\u00f3n Mart\u00edn","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2022072817544503100_dkac178-B9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2022072817544503100_dkac178-B10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022072817544503100_dkac178-B11","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2106\/JBJS.15.00988","article-title":"Development and validation of a preoperative surgical site infection risk score for primary or revision knee and hip arthroplasty","volume":"98","author":"Everhart","year":"2016","journal-title":"J Bone Jt Surg Am"},{"key":"2022072817544503100_dkac178-B12","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/CORR.0000000000001171","article-title":"Lower success rate of d\u00e9bridement and implant retention in late acute versus early acute periprosthetic joint infection caused by Staphylococcus spp. results from a matched cohort study","volume":"478","author":"Wouthuyzen-Bakker","year":"2020","journal-title":"Clin Orthop Relat Res"},{"key":"2022072817544503100_dkac178-B13","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.arth.2021.01.074","article-title":"Analysis of culture positive first and second stage procedures in periprosthetic knee and hip joint infections","volume":"36","author":"Frank","year":"2021","journal-title":"J Arthroplasty"},{"key":"2022072817544503100_dkac178-B14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jgar.2021.03.026","article-title":"Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review","volume":"25","author":"Matt","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2022072817544503100_dkac178-B15","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of Osteomyelitis in adult patients: A randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2022072817544503100_dkac178-B16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/antibiotics10060656","article-title":"Dalbavancin for the treatment of prosthetic joint infections: A narrative review","volume":"10","author":"Buz\u00f3n-Mart\u00edn","year":"2021","journal-title":"Antibiotics"},{"key":"2022072817544503100_dkac178-B17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2022072817544503100_dkac178-B18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijid.2018.11.011","article-title":"In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source","volume":"78","author":"Azrad","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2022072817544503100_dkac178-B19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fmicb.2020.00553","article-title":"Effect of dalbavancin on staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds","volume":"11","author":"\u017diemyt\u0117","year":"2020","journal-title":"Front Microbiol"},{"key":"2022072817544503100_dkac178-B20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1302\/2058-5241.4.180092","article-title":"Periprosthetic joint infection: current concepts and outlook","volume":"4","author":"Izakovicova","year":"2019","journal-title":"EFORT Open Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/8\/2274\/45180602\/dkac178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/8\/2274\/45180602\/dkac178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T18:09:09Z","timestamp":1659031749000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/8\/2274\/6604642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,6,9]]},"published-print":{"date-parts":[[2022,7,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac178","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,6,9]]}}}